Agenus

iTeos Therapeutics' mid-stage trial results show its drug, when combined with GSK's immunotherapy, shrank lung tumors in twice as many patients compared to GSK's therapy alone. The trial raised safety concerns due to three treatment-related deaths from immune-related inflammation. Despite previous failures of TIGIT-targeting drugs, iTeos' data could rekindle interest in the target, with further data expected to clarify the combination's impact on survival and disease progression.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Brazil emerges as a key hub for oncology clinical trials, with Roche leading in trials for drugs like Atezolizumab and Pertuzumab. The country focuses on prevalent cancers, with NSCLC trials dominating. Phase III trials are prevalent, supported by CROs, indicating Brazil's role in global cancer research.

In July 2024, the FDA made significant strides in cancer treatment approvals and designations, including the approval of FoundationOne Liquid CDx for BRCA-mutated mCRPC and Guardant Shield for colorectal cancer detection. Fast track designations were granted to therapies like OBX-115 for melanoma and AIC100 for thyroid cancer. The FDA also accepted BLAs for treatments targeting SR-aGVHD and EBV+ PTLD, and mandated phase assessments for NSCLC perioperative regimens, aiming to improve patient outcomes.

Agenus announced a $100M royalty financing agreement with Ligand Pharmaceuticals to support its BOT/BAL program, aiming for a Phase 3 study in colorectal cancer. The company reported a Q1 2024 net loss of $63.5M, with a cash balance of $52.9M. Agenus is preparing for a BLA submission and anticipates significant developments in its cancer treatment programs.

FDA fast-tracked botensilimab plus balstilimab for non-MSI-H/dMMR metastatic colorectal cancer treatment. A phase 2 trial is ongoing, with a phase 3 trial expected in 2023. Phase 1a/b trial showed a 23% ORR in MSS refractory mCRC patients. Common TRAEs included diarrhea, nausea, and fatigue.

The article reviews drugs and medical devices for glioblastoma (GBM) treatment, analyzing their modes of action, including radiation, targeting glioma cells, and immunotherapy. Most treatments are in early development stages, with Optune showing some efficacy. Early diagnosis and improved preclinical studies are emphasized for better treatment outcomes. The article also discusses drug delivery challenges, societal and economic aspects, and the importance of the orphan drug status in accelerating GBM therapy development.